GO TO: Recent Comment Letters
ALL |
All 10-K/Qs
Large
Mid
Small
Micro
|
Earnings Release
Proxy
|
SORT BY :
Most Recent
Company Name
| Company | Time | Size | View | Financials | Document | SEC | Period | Revenue MRQ | Assets | EPS Diluted | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | 11/6/2026 8:11:42 AM | Micro | View | Financials | 10-Q | SEC | 3Q 2026 ending: 9/30/2026 | Rev: $2,830,000 +281.9% | Assets $47,189,000 | EPS -$2.09 | |
| Aligos Therapeutics, Inc. (ALGS) | 11/6/2026 8:01:18 AM | View | Financials | Earnings | SEC | 3Q 2026 | Rev $2,830,000 +281.9% | Assets $47,189,000 | EPS -$2.09 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 8/6/2026 8:16:05 AM | Micro | View | Financials | 10-Q | SEC | 2Q 2026 ending: 6/30/2026 | Rev: $27,778,000 +2,778.5% | Assets $66,327,000 | EPS -$0.14 | |
| Aligos Therapeutics, Inc. (ALGS) | 8/6/2026 8:02:36 AM | View | Financials | Earnings | SEC | 2Q 2026 | Rev $27,778,000 +2,778.5% | Assets $66,327,000 | EPS -$0.14 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 5/7/2026 4:39:39 PM | Micro | View | Financials | 10-Q | SEC | 1Q 2026 ending: 3/31/2026 | Rev: $2,830,000 +810.0% | Assets $64,558,000 | EPS -$2.21 | |
| Aligos Therapeutics, Inc. (ALGS) | 5/7/2026 4:19:54 PM | View | Financials | Earnings | SEC | 1Q 2026 | Rev $2,830,000 +810.0% | Assets $64,558,000 | EPS -$2.21 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 4/29/2026 4:33:15 PM | View | Proxy | SEC | Y 2025 | ||||||
| Aligos Therapeutics, Inc. (ALGS) | 3/5/2026 8:15:33 AM | Micro | View | Financials | 10-K | SEC | Y 2025 ending: 12/31/2025 | Rev: $2,186,000 -39.5% | Assets $88,533,000 | EPS -$2.45 | |
| Aligos Therapeutics, Inc. (ALGS) | 3/5/2026 8:03:09 AM | View | Financials | Earnings | SEC | Y 2025 | Rev $169,000 -72.1% | Assets $88,533,000 | EPS -$2.01 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 11/6/2025 8:42:18 AM | Micro | View | Financials | 10-Q | SEC | 3Q 2025 ending: 9/30/2025 | Rev: $741,000 -40.7% | Assets $109,764,000 | EPS -$3.04 | |
| Aligos Therapeutics, Inc. (ALGS) | 11/6/2025 8:32:07 AM | View | Financials | Earnings | SEC | 3Q 2025 | Rev $741,000 -40.7% | Assets $109,764,000 | EPS -$3.04 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 8/6/2025 4:23:30 PM | Micro | View | Financials | 10-Q | SEC | 2Q 2025 ending: 6/30/2025 | Rev: $965,000 -9.0% | Assets $134,706,000 | EPS -$1.53 | |
| Aligos Therapeutics, Inc. (ALGS) | 8/6/2025 4:08:14 PM | View | Financials | Earnings | SEC | 2Q 2025 | Rev $965,000 -9.0% | Assets $134,706,000 | EPS -$1.53 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 5/6/2025 8:24:43 AM | Small | View | Financials | 10-Q | SEC | 1Q 2025 ending: 3/31/2025 | Rev: $311,000 -55.2% | Assets $150,699,000 | EPS -$2.11 | |
| Aligos Therapeutics, Inc. (ALGS) | 5/6/2025 8:01:20 AM | View | Financials | Earnings | SEC | 1Q 2025 | Rev $311,000 -55.2% | Assets $150,699,000 | EPS -$2.11 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 4/28/2025 4:07:06 PM | View | Proxy | SEC | Y 2024 | ||||||
| Aligos Therapeutics, Inc. (ALGS) | 3/10/2025 8:12:28 AM | Micro | View | Financials | 10-K | SEC | Y 2024 ending: 12/31/2024 | Rev: $3,611,000 -41.7% | Assets $70,094,000 | EPS -$20.94 | |
| Aligos Therapeutics, Inc. (ALGS) | 3/10/2025 8:01:55 AM | View | Financials | Earnings | SEC | Y 2024 | Rev $606,000 -9.8% | Assets $70,094,000 | EPS -$13.10 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 11/6/2024 4:43:48 PM | Micro | View | Financials | 10-Q | SEC | 3Q 2024 ending: 9/30/2024 | Rev: $1,250,000 +15.2% | Assets $88,426,000 | EPS -$3.07 | |
| Aligos Therapeutics, Inc. (ALGS) | 11/6/2024 4:06:15 PM | View | Financials | Earnings | SEC | 3Q 2024 | Rev $1,250,000 +15.2% | Assets $88,426,000 | EPS -$3.07 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 8/6/2024 4:28:30 PM | Micro | View | Financials | 10-Q | SEC | 2Q 2024 ending: 6/30/2024 | Rev: $1,061,000 -75.3% | Assets $108,811,000 | EPS $0.03 | |
| Aligos Therapeutics, Inc. (ALGS) | 8/6/2024 4:09:43 PM | View | Financials | Earnings | SEC | 2Q 2024 | Rev $1,061,000 -75.3% | Assets $108,811,000 | EPS $0.03 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 5/7/2024 4:24:55 PM | Micro | View | Financials | 10-Q | SEC | 1Q 2024 ending: 3/31/2024 | Rev: $694,000 +395.7% | Assets $127,902,000 | EPS -$5.58 | |
| Aligos Therapeutics, Inc. (ALGS) | 5/7/2024 4:12:19 PM | View | Financials | Earnings | SEC | 1Q 2024 | Rev $694,000 +395.7% | Assets $127,902,000 | EPS -$5.58 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 4/29/2024 4:01:46 PM | View | Proxy | SEC | Y 2023 | ||||||
| Aligos Therapeutics, Inc. (ALGS) | 3/12/2024 4:29:13 PM | Small | View | Financials | 10-K | SEC | Y 2023 ending: 12/31/2023 | Rev: $6,191,000 | Assets $151,527,000 | EPS -$34.20 | |
| Aligos Therapeutics, Inc. (ALGS) | 3/12/2024 4:07:48 PM | View | Financials | Earnings | SEC | Y 2023 | Rev $672,000 | Assets $151,527,000 | EPS $0.39 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 11/2/2023 4:38:33 PM | Micro | View | Financials | 10-Q | SEC | 3Q 2023 ending: 9/30/2023 | Rev: $1,085,000 | Assets $85,852,000 | EPS -$10.37 | |
| Aligos Therapeutics, Inc. (ALGS) | 11/2/2023 4:08:11 PM | View | Financials | Earnings | SEC | 3Q 2023 | Rev $1,085,000 | Assets $85,852,000 | EPS -$10.37 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 8/3/2023 4:40:10 PM | Micro | View | Financials | 10-Q | SEC | 2Q 2023 ending: 6/30/2023 | Rev: $4,294,000 | Assets $106,130,000 | EPS -$0.43 | |
| Aligos Therapeutics, Inc. (ALGS) | 8/3/2023 4:09:39 PM | View | Financials | Earnings | SEC | 2Q 2023 | Rev $4,294,000 | Assets $106,130,000 | EPS -$0.43 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 6/2/2023 4:08:12 PM | View | Proxy | SEC | Y 2022 | ||||||
| Aligos Therapeutics, Inc. (ALGS) | 5/4/2023 4:33:10 PM | Micro | View | Financials | 10-Q | SEC | 1Q 2023 ending: 3/31/2023 | Rev: $140,000 -94.6% | Assets $121,738,000 | EPS -$0.53 | |
| Aligos Therapeutics, Inc. (ALGS) | 5/4/2023 4:12:35 PM | View | Financials | Earnings | SEC | 1Q 2023 | Rev $140,000 -94.6% | Assets $121,738,000 | EPS -$0.53 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 4/28/2023 5:00:34 PM | View | Proxy | SEC | Y 2022 | ||||||
| Aligos Therapeutics, Inc. (ALGS) | 3/9/2023 4:30:33 PM | Small | View | Financials | 10-K | SEC | Y 2022 ending: 12/31/2022 | Assets $146,693,000 | EPS -$2.25 | ||
| Aligos Therapeutics, Inc. (ALGS) | 3/9/2023 4:06:20 PM | View | Financials | Earnings | SEC | Y 2022 | Rev $0 | Assets $146,693,000 | EPS -$0.51 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 11/2/2022 4:27:33 PM | Small | View | Financials | 10-Q | SEC | 3Q 2022 ending: 9/30/2022 | Assets $164,069,000 | EPS -$0.44 | ||
| Aligos Therapeutics, Inc. (ALGS) | 11/2/2022 4:10:09 PM | View | Financials | Earnings | SEC | 3Q 2022 | Rev $0 | Assets $164,069,000 | EPS -$0.44 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 8/4/2022 4:59:16 PM | Small | View | Financials | 10-Q | SEC | 2Q 2022 ending: 6/30/2022 | Assets $182,523,000 | EPS -$0.47 | ||
| Aligos Therapeutics, Inc. (ALGS) | 8/4/2022 4:13:33 PM | View | Financials | Earnings | SEC | 2Q 2022 | Rev $0 | Assets $182,523,000 | EPS -$0.47 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 5/4/2022 4:47:35 PM | Small | View | Financials | 10-Q | SEC | 1Q 2022 ending: 3/31/2022 | Rev: $2,571,000 +182.5% | Assets $210,470,000 | EPS -$0.84 | |
| Aligos Therapeutics, Inc. (ALGS) | 5/4/2022 4:08:46 PM | View | Financials | Earnings | SEC | 1Q 2022 | Rev $2,571,000 +182.5% | Assets $210,470,000 | EPS -$0.84 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 4/29/2022 6:26:53 AM | View | Proxy | SEC | Y 2021 | ||||||
| Aligos Therapeutics, Inc. (ALGS) | 3/10/2022 4:34:34 PM | Small | View | Financials | 10-K | SEC | Y 2021 ending: 12/31/2021 | Rev: $4,359,000 | Assets $235,369,000 | EPS -$3.22 | |
| Aligos Therapeutics, Inc. (ALGS) | 3/10/2022 4:06:55 PM | View | Financials | Earnings | SEC | Y 2021 | Rev $367,000 | Assets $235,369,000 | EPS -$0.91 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 11/4/2021 4:33:32 PM | Small | View | Financials | 10-Q | SEC | 3Q 2021 ending: 9/30/2021 | Rev: $1,537,000 | Assets $263,068,000 | EPS -$0.78 | |
| Aligos Therapeutics, Inc. (ALGS) | 11/4/2021 4:11:20 PM | View | Financials | Earnings | SEC | 3Q 2021 | Rev $1,537,000 | Assets $263,068,000 | EPS -$0.78 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 8/5/2021 4:53:43 PM | Small | View | Financials | 10-Q | SEC | 2Q 2021 ending: 6/30/2021 | Rev: $1,545,000 | Assets $211,876,000 | EPS -$0.79 | |
| Aligos Therapeutics, Inc. (ALGS) | 8/5/2021 4:11:46 PM | View | Financials | Earnings | SEC | 2Q 2021 | Rev $1,545,000 | Assets $211,876,000 | EPS -$0.79 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 5/10/2021 4:33:50 PM | Small | View | Financials | 10-Q | SEC | 1Q 2021 ending: 3/31/2021 | Rev: $910,000 | Assets $234,540,000 | EPS -$0.74 | |
| Aligos Therapeutics, Inc. (ALGS) | 5/10/2021 4:08:27 PM | View | Financials | Earnings | SEC | 1Q 2021 | Rev $910,000 | Assets $234,540,000 | EPS -$0.74 | Export Earnings Model | |
| Aligos Therapeutics, Inc. (ALGS) | 4/27/2021 4:19:27 PM | View | Proxy | SEC | Y 2020 | ||||||
| Aligos Therapeutics, Inc. (ALGS) | 3/23/2021 4:35:14 PM | Small | View | Financials | 10-K | SEC | Y 2020 ending: 12/31/2020 | Assets $265,302,000 | EPS -$10.87 | ||
| Aligos Therapeutics, Inc. (ALGS) | 3/23/2021 4:06:26 PM | View | Financials | Earnings | SEC | Y 2020 | Assets $265,302,000 | EPS $15.33 | Export Earnings Model | ||
| Aligos Therapeutics, Inc. (ALGS) | 11/25/2020 5:36:16 PM | Micro | View | Financials | 10-Q | SEC | 3Q 2020 ending: 9/30/2020 | Assets $92,183,000 | EPS -$11.00 |